Comparative Analysis of Gradient Diffusion and Disk Diffusion with Agar Dilution for Susceptibility Testing of Elizabethkingia anophelis

Chien-Tung Chiu 1, Chung-Hsu Lai 2,3, Yi-Han Huang 3, Chih-Hui Yang 4 and Jiun-Nong Lin 1,2,3,*

1 Department of Critical Care Medicine, E-Da Hospital, I-Shou University, Kaohsiung 824, Taiwan; chiu168@gmail.com
2 Department of Internal Medicine, Division of Infectious Diseases, E-Da Hospital, I-Shou University, Kaohsiung 824, Taiwan; laich6363@yahoo.com.tw
3 School of Medicine, College of Medicine, I-Shou University, Kaohsiung 824, Taiwan; je091410show@hotmail.com
4 Department of Biological Science and Technology, Meiho University, Pingtung 912, Taiwan; puppylovefu@gmail.com
* Correspondence: jinoli@kmu.edu.tw

Abstract: Elizabethkingia anophelis has recently emerged as a cause of life-threatening infections. This study compared the results of antimicrobial susceptibility testing (AST) conducted for E. anophelis through different methods. E. anophelis isolates collected between January 2005 and June 2019 were examined for their susceptibility to 14 antimicrobial agents by using disk diffusion, gradient diffusion (Etest; bioMérieux S.A., Marcy l’Etoile, France), and agar dilution methods. The agar dilution method was the reference assay. According to the agar dilution method, the isolates exhibited the highest susceptibility to minocycline (100%), doxycycline (97.6%), rifampin (95.2%), and levofloxacin (78.6%). A very major error rate of >1.5% was observed for nine antibiotics tested using the disk diffusion method. The overall categorical agreement rate between the disk diffusion and agar dilution methods was 74.8%, and ceftazidime, minocycline, levofloxacin, and rifampin met the minimum requirements for discrepancy and agreement rates. The Etest method tended to produce lower log_{10} minimum inhibitory concentrations for the antibiotics, except for trimethoprim–sulfamethoxazole and rifampin; the method resulted in very major errors for nine antibiotics. The overall essential and categorical agreement rates between the Etest and agar dilution methods were 67.3% and 76.1%, respectively. The Etest method demonstrated acceptable discrepancy and agreement rates for ceftazidime, minocycline, doxycycline, levofloxacin, and rifampin. AST results obtained through the disk diffusion and Etest methods for multiple antibiotics differed significantly from those obtained using the agar dilution method. These two assays should not be a routine alternative for AST for E. anophelis.

Keywords: Elizabethkingia anophelis; antimicrobial susceptibility testing; agar dilution; gradient diffusion; disk diffusion

1. Introduction

Members of the genus Elizabethkingia are aerobic, Gram-negative, nonfermenting, nonmotile, catalase-positive, oxidase-positive, and indole-positive bacilli distributed in natural soil and water environments [1–4]. Since its first identification by Elizabeth O. King in 1959 [4], Elizabethkingia has been reported to cause human infections. Currently, six species constitute the genus Elizabethkingia, namely, E. meningoseptica, E. miricola, E. anophelis, E. bruuniana, E. ursingii, and E. occulta [5]. E. anophelis was initially isolated in the midgut of the Anopheles gambiae mosquito in 2011 [6], and this pathogen has been identified to be the species most commonly associated with human infections, particularly in immunocompromised patients [7–13]. The overall mortality rate of patients infected with E. anophelis ranges from 24% to 60% [7–13]. Several outbreaks of life-threatening infections caused
by *E. anophelis* have been described in many countries, including Singapore, Hong Kong, South Korea, Taiwan, and the United States [7–13].

Several studies have reported that *E. anophelis* strains typically expressed resistance to multiple antibiotics, but others have revealed that they demonstrated susceptibility to some antibiotics such as certain β-lactams, fluoroquinolones, and sulfa drugs [7–13]. These inconsistent antimicrobial susceptibility testing (AST) results can be attributed to the use of different testing methods, such as disk diffusion, gradient diffusion, broth dilution, and agar dilution assays.

According to Clinical and Laboratory Standards Institute (CLSI) guidelines [14], breakpoints of antimicrobial agents against “other non-Enterobacteriaceae” are only determined using broth dilution or agar dilution minimum inhibitory concentration (MIC) testing. Despite the inconsistent AST results reported by numerous studies, no study has evaluated the accuracy of non-reference testing methods for *E. anophelis*. To fill this research gap, we used the CLSI-recommended standard agar dilution method as a reference assay and examined the concordance of AST results obtained from gradient diffusion and disk diffusion methods for clinical *E. anophelis* isolates.

2. Materials and Methods

2.1. Ethics

This study was approved by the Institutional Review Board of E-Da Hospital, an approximately 1000-bed university-affiliated medical center in Kaohsiung, Taiwan (EMRP-107-139). All experiments in this study were conducted in accordance with the Declaration of Helsinki and national standards of Taiwan. The need for patient informed consent was waived because the AST of microorganisms that were obtained from routine clinical cultures involved minimal risk of harm to patients.

2.2. Study Setting and Design

The database of clinical microbiology laboratory of E-Da Hospital was searched for microbial cultures that yielded *Elizabethkingia* species from January 2005 to June 2019. All isolates used in this study were routinely collected from patients according to their clinical requirements. These isolates were reserved as glycerol stocks at −80 °C until use. Accurate species of the stored *Elizabethkingia* isolates were re-identified through 16S ribosomal ribonucleic acid gene sequencing as described in our previous study [11]. Isolates recognized as *E. anophelis* were included in this study. The MICs and antimicrobial susceptibility patterns of 14 antimicrobial agents against all *E. anophelis* isolates were concomitantly determined using the agar dilution, gradient diffusion, and disk diffusion methods. The CLSI-recommended agar dilution method was used as a reference assay.

2.3. Agar Dilution Assay

MICs obtained using the agar dilution method were performed in accordance with CLSI guidelines [15]. In brief, the isolates were spread on Mueller–Hinton agar plates (Becton Dickinson, Sparks, MD, USA) for overnight culture at 35 °C; subsequently, new colonies were inoculated into Mueller–Hinton broth tubes. Bacterial suspensions were adjusted to a turbidity equivalent to that of a 0.5 McFarland standard. AST plates (9 cm in diameter) were prepared by adding 14 serially twofold-diluted antibiotics to Mueller–Hinton agar plates (Table 1). A bacterial suspension of 1 μL (approximately 10^5 colony-forming unit (CFU)/mL) from a prepared 0.5 McFarland standard suspension was added as a spot, and 2 spots per strain were added to each plate. Twenty-four strains were tested per plate. These plates were incubated at 35 °C in ambient air for 16–20 h.
Table 1. The ranges of antimicrobial concentrations used in this study.

| Antimicrobial Agent                      | Susceptibility Testing Assay |
|-----------------------------------------|-------------------------------|
|                                         | Agar Dilution (mg/L) | Disk Diffusion (µg) | Etest (mg/L) |
| Piperacillin                             | 2–256                        | 100                | 0.016–256    |
| Piperacillin–tazobactam                 | 2/4–256/4                    | 100/10             | 0.016/4–256/4|
| Ceftazidime                             | 8–256                        | 30                 | 0.016–256    |
| Cefepime                                | 1–128                        | 30                 | 0.016–256    |
| Gentamicin                              | 1–128                        | 10                 | 0.016–256    |
| Amikacin                                | 2–256                        | 30                 | 0.016–256    |
| Minocycline                             | 0.0625–2                     | 30                 | 0.016–256    |
| Doxycycline                             | 0.25–16                      | 30                 | 0.016–256    |
| Tigecycline                             | 0.25–32                      | 15                 | 0.016–256    |
| Ciprofloxacin                           | 0.25–32                      | 5                  | 0.002–32     |
| Levofloxacin                            | 0.25–32                      | 5                  | 0.002–32     |
| Trimethoprim–sulfamethoxazole           | 0.5/9.5–32/608               | 1.25/23.75         | 0.002/0.38 – 32/608 |
| Rifampin                                | 0.25–16                      | 5                  | 0.016–256    |
| Vancomycin                              | 2–256                        | 30                 | 0.016–256    |

Sources of standard powders: ciprofloxacin and levofloxacin were obtained from Sigma-Aldrich (St. Louis, MO, USA), and others were bought from Cyrsbience (Taipei, Taiwan).

2.4. Disk Diffusion Assay

Disk susceptibility tests were performed using the CLSI-recommended standard technique [16]. The suspensions 0.5 McFarland standard were swabbed onto the Mueller–Hinton agar plates. Filter paper disks (Becton Dickinson) impregnated with the 14 antimicrobial agents tested in this study were placed on top of the agar plates; Table 1 lists the concentrations of antimicrobial agents impregnated on the disks. These plates were incubated at 35°C in ambient air for 16–20 h. After incubation, the size of the inhibition zone around each disk was measured.

2.5. Gradient Diffusion Assay

The gradient diffusion assay was performed using Etest according to the manufacturer’s instructions (bioMérieux S.A., Marcy l’Etoile, France). The bacterial suspension preparation, inoculum, and incubation procedures were the same as those used for the disk diffusion method. Table 1 presents the gradient concentrations of the 14 antibiotics on the strips.

2.6. Susceptibility Interpretation

The MIC interpretive criteria for the results of agar dilution and Etest methods were adopted from CLSI standards for “other non-Enterobacteriaceae” [14], except for tigecycline, rifampin, and vancomycin. The disk diffusion breakpoints were not established for “other non-Enterobacteriaceae” by CLSI. The susceptibility results by the disk diffusion method were determined according to the CLSI diameter interpretive criteria for Acinetobacter species because their MIC breakpoints were the same as those of “other non-Enterobacteriaceae” [14]. The susceptibility testing results of tigecycline were interpreted according to Enterobacteriaceae breakpoints provided by the U.S. Food and Drug Administration (FDA) (MIC: susceptible, ≤2 mg/L; intermediate, 4 mg/L; resistant, ≥8 mg/L; zone diameter: susceptible, ≥19 mm; intermediate, 15–18 mm; resistant, ≤14 mm) [17]. For rifampin and vancomycin, the susceptibility criteria of zone diameters and MICs were interpreted according to CLSI standards for Enterococcus species [14].

2.7. Comparative Performance Data

The agreement and discrepancy among the different testing methods were evaluated as described previously [18,19]. The very major error (discrepancy) rate was defined as the percentage of the number of isolates with false-susceptible results divided by the number of resistant isolates; major error (discrepancy) rate was defined as the percentage of the
number of isolates with false-resistant results divided by the number of susceptible isolates, and minor error (discrepancy) rate was defined as the percentage of the number of isolates with intermediate results from the evaluated method and susceptible or resistant results from the reference method, or vice versa, divided by the total number of isolates. The essential agreement rate was defined as the percentage of the number of isolates with MICs—provided by the evaluated method—within ±1 log₂ dilution of the reference MIC divided by the number of isolates tested. The categorical agreement rate was defined as the percentage of the number of isolates—tested using the evaluated method—with the same categorical interpretation (susceptible, intermediate, and resistant) as the reference divided by the total number of isolates examined. According to U.S. FDA criteria [18,19], the acceptable values of the very major error, major error, and minor error rates are ≤1.5%, ≤3%, and ≤10%, respectively. Both essential and categorical agreement rates are considered acceptable if they are ≥90%.

3. Results

3.1. Susceptibility

According to the CLSI-recommended agar dilution method, the susceptibility rates were as follows: minocycline, 100%; doxycycline, 97.6%; rifampin, 95.2%; levofloxacin, 78.6%; ciprofloxacin, 8.3%; tigecycline, 4.8%; trimethoprim–sulfamethoxazole, 1.2%; and others, 0%. The disk diffusion method demonstrated that the among the 14 antibiotics, the isolates exhibited adequate susceptibility to minocycline (100%), doxycycline (98.8%), levofloxacin (79.8%), and rifampin (85.7%; Table 2). As revealed by the Etest method, the isolates exhibited high rates of susceptibility to minocycline (100%), doxycycline (97.6%), tigecycline (77.4%), ciprofloxacin (75%), levofloxacin (79.8%), and rifampin (94%) but showed extremely low rates of susceptibility to the other antibiotics (<15%).

Table 2. Antimicrobial MICs (mg/L) and susceptible rates of 84 E. anophelis isolates determined using the agar dilution, Etest, and disk diffusion methods.

| Antimicrobial Agent                  | Agar Dilution | Disk Diffusion | Etest |
|--------------------------------------|---------------|----------------|-------|
|                                      | MIC Range     | MIC₅₀ | % Sᵃ | MIC Range     | MIC₅₀ | % Sᵃ | MIC Range     | MIC₅₀ | % Sᵃ |
| Piperacillin                         | 128–>256      | >256  | 0    | 4.8          | 8–>256 | >256  | 2.4          |       |
| Piperacillin–tazobactam              | 256/4–>256/4  | >256  | 0    | 22.6         | 8/4–>256/4 | >256/4 | 4.8          |       |
| Ceftazidime                          | 256–>256      | >256  | 0    | 0            | 48–>256 | >256  | 0            |       |
| Cefepime                             | 32–>128       | >128  | 21.4 | 1.5–>256     | >256  | >256  | 2.4          |       |
| Gentamicin                           | 8–>128        | >128  | 9.5  | 3–>256       | 64    | >256  | 13.1         |       |
| Amikacin                             | 32–>256       | >256  | 6    | 12–>256      | >256  | >256  | 3.6          |       |
| Minocycline                          | 0.125–1       | 0.25  | 100  | 0.023–0.38   | 0.125 | 0.19  | 100          |       |
| Doxycycline                          | 1–16          | 2     | 97.6 | 0.16–16      | 1     | 2     | 97.6         |       |
| Tigecycline                          | 2–32          | 8     | 48   | 0.125–8      | 1.5   | 3     | 77.4         |       |
| Ciprofloxacin                        | 1–>32         | 2     | 83   | 0.038–>32   | 0.5   | 32    | 75           |       |
| Levofloxacin                         | 0.5–>32       | 2     | 78.6 | 0.038–>32   | 0.38  | >32   | 79.8         |       |
| Trimethoprim–sulfamethoxazole        | 2/38–32/608   | 8/152 | 16/304 | 1.2 | 0.38–7.22–>32/608 | >32/608 | >32/608 | 4.8 |
| Rifampin                             | <0.25–0.5     | 0.5   | 95.2 | 0.125–>32   | 0.38  | 0.75  | 94           |       |
| Vancomycin                           | 8–256         | 32    | 0    | 25           | 3–32  | 8     | 16           | 9.5   |

ᵃ S, susceptible.

3.2. MIC Determination

A total of 84 E. anophelis isolates were included for AST in which the disk diffusion, Etest, and agar dilution methods were concomitantly performed. Table 2 presents the antimicrobial susceptibility patterns. In general, the Etest method tended to yield lower MICs than did the agar dilution method for most antimicrobial agents. For example, the MIC of tigecycline determined using the Etest method ranged from 0.125 to 8 mg/L, whereas that determined using the agar dilution method ranged from 2 to 32 mg/L. The MIC₅₀ levels for the following antibiotics were obtained using the Etest and agar dilution methods, respectively: minocycline, 0.125 and 0.25 mg/L; doxycycline, 1 and 2 mg/L; tigecycline, 1.5 and 8 mg/L; ciprofloxacin, 0.5 and 2 mg/L; levofloxacin, 0.38 and 2 mg/L; and rifampin, 0.38 and 0.5 mg/L. Of the 14 antibiotics, minocycline was the most active.
against *E. anophelis* and had the lowest MIC<sub>50</sub> and MIC<sub>90</sub> determined using both the Etest and agar dilution methods.

### 3.3. Discrepancy and Agreement Rates between Disk Diffusion and Agar Dilution Methods

The results revealed a very major error rate of <1.5% for ceftazidime, minocycline, levofloxacin, and rifampin; the very major error rate was also noted to be high for the other antibiotics (Table 3). The disk diffusion method indicated particularly high, very major error rates for piperacillin–tazobactam (22.6%), cefepime (21.4%), doxycycline (100%), tigecycline (50.9%), and vancomycin (25.3%). Trimethoprim–sulfamethoxazole was the only antibiotic with a major error (100%). The results also revealed acceptable categorical agreement rates (>90%) for ceftazidime, amikacin, minocycline, doxycycline, levofloxacin, trimethoprim–sulfamethoxazole, and rifampin (Figure 1). The overall rate of categorical agreement between the disk diffusion and agar dilution methods was 74.8%. Of the 14 antimicrobial agents, only ceftazidime, minocycline, levofloxacin, and rifampin met the minimum requirements for discrepancy and categorical agreement rates.

#### Table 3. Comparison of the disk diffusion and Etest methods with the agar dilution method for antimicrobial susceptibility testing of 84 *E. anophelis* isolates.

| Antimicrobial Agent | Technique | Isolate no. of MIC log<sub>2</sub> Dilutions Differ from the Agar Dilution | Essential Agreement (%) | Interpretive Errors (%) | Categorical Agreement (%) |
|---------------------|-----------|-------------------------------------------------|------------------------|------------------------|--------------------------|
|                     |           | ≤−3 −2 −1 0 +1 +2 ≥+3                          | Very Major  | Major | Minor |                  |                        |
| Piperacillin         | Disk diffusion | – – – – – – –                               | 91.7 | N/A | 4.8 | 13.1    | 82.1                  |
|                     | Etest     | – – – – – – –                               | 84.5 | N/A | 4.8 | 11.9    | 83.3                  |
| Piperacillin–tazobactam | Disk diffusion | – – – – – – –                               | 96.4 | N/A | 4.8 | 0       | 100                  |
|                     | Etest     | – – – – – – –                               | 91.7 | N/A | 4.8 | 13.1    | 82.1                  |
| Cefazidime          | Disk diffusion | – – – – – – –                               | 72.6 | 96.4| 2.4  | 16.7    | 81                   |
|                     | Etest     | – – – – – – –                               | 54.8 | 96.4| 2.4  | 16.7    | 81                   |
| Gentamicin          | Disk diffusion | – – – – – – –                               | 72.6 | 96.4| 2.4  | 16.7    | 81                   |
|                     | Etest     | – – – – – – –                               | 54.8 | 96.4| 2.4  | 16.7    | 81                   |
| Amikacin            | Disk diffusion | – – – – – – –                               | 72.6 | 96.4| 2.4  | 16.7    | 81                   |
|                     | Etest     | – – – – – – –                               | 54.8 | 96.4| 2.4  | 16.7    | 81                   |
| Minocycline         | Disk diffusion | – – – – – – –                               | 72.6 | 96.4| 2.4  | 16.7    | 81                   |
|                     | Etest     | – – – – – – –                               | 54.8 | 96.4| 2.4  | 16.7    | 81                   |
| Doxycycline         | Disk diffusion | – – – – – – –                               | 72.6 | 96.4| 2.4  | 16.7    | 81                   |
|                     | Etest     | – – – – – – –                               | 54.8 | 96.4| 2.4  | 16.7    | 81                   |
| Tigecycline         | Disk diffusion | – – – – – – –                               | 72.6 | 96.4| 2.4  | 16.7    | 81                   |
|                     | Etest     | – – – – – – –                               | 54.8 | 96.4| 2.4  | 16.7    | 81                   |
| Ciprofloxacin       | Disk diffusion | – – – – – – –                               | 72.6 | 96.4| 2.4  | 16.7    | 81                   |
|                     | Etest     | – – – – – – –                               | 54.8 | 96.4| 2.4  | 16.7    | 81                   |
| Levofloxacin        | Disk diffusion | – – – – – – –                               | 72.6 | 96.4| 2.4  | 16.7    | 81                   |
|                     | Etest     | – – – – – – –                               | 54.8 | 96.4| 2.4  | 16.7    | 81                   |
| Vancomycin          | Disk diffusion | – – – – – – –                               | 72.6 | 96.4| 2.4  | 16.7    | 81                   |
|                     | Etest     | – – – – – – –                               | 54.8 | 96.4| 2.4  | 16.7    | 81                   |

#### 3.4. Discrepancy and Agreement Rates between Etest and Agar Dilution Methods

Compared with the agar dilution method, the Etest method tended to produce lower log<sub>2</sub> MICs for the antimicrobial agents, except for trimethoprim–sulfamethoxazole and rifampin (Table 3). The essential agreement rates were acceptable (≥90%) only for piperacillin, ceftazidime, and doxycycline (Figure 2). By contrast, the essential agreement rates were substantially low for tigecycline, ciprofloxacin, levofloxacin, trimethoprim–sulfamethoxazole, and vancomycin (<50%). Acceptable very major error rates (<1.5%) were determined for ceftazidime, minocycline, doxycycline, levofloxacin, and rifampin. Similar to the results obtained using the disk diffusion method, trimethoprim–sulfamethoxazole was the only agent with a major error (100%). The rate of categorical agreement (90%) between the two methods was high for piperacillin (95.2%), ceftazidime (100%), minocycline (100%), doxycycline (98.8%), levofloxacin (98.8%), trimethoprim–sulfamethoxazole (94%), and rifampin (98.8%) (Figure 2). The categorical agreement rate was extremely low for tigecycline.
Antibiotics 2021, 10, x FOR PEER REVIEW 6 of 10

The mechanism for the low rifampin MICs of E. anophelis is not clear and warrants further investigation. It is known that rifampicin inhibits bacterial DNA-dependent RNA polymerase. Sulfamethoxazole and trimethoprim inhibit dihydrofolate reductase and dihydropteroate synthase, respectively. Fluoroquinolones (ciprofloxacin and levofloxacin) act by inhibiting DNA topoisomerases (DNA gyrase and topoisomerase IV). Carboxypeptidase, β-lactamases, β-lactamase inhibitors, penicillins, cephalosporins, carbapenems, and aztreonam are used to suppress bacterial cell wall synthesis. Aminoglycosides (gentamicin and amikacin) and tetracyclines/glycylcycline (minocycline, doxycycline, and tigecycline) inhibit protein synthesis by binding to the 30S ribosomal subunit. Fluoroquinolones (ciprofloxacin and levofloxacin) act by inhibiting DNA topoisomerases (DNA gyrase and topoisomerase IV).

The disk diffusion method is an inexpensive, convenient, and excellent AST approach for many microorganisms. Nevertheless, our study revealed that this method exhibited poor performance in the AST of E. anophelis. Only ceftazidime, minocycline, doxycycline, levofloxacin, and rifampin demonstrated acceptable discrepancy and agreement rates.

Among the 14 antimicrobial agents tested in this study, only minocycline, doxycycline, rifampin, and levofloxacin were mostly effective against E. anophelis. The essential and categorical agreement between the Etest and agar dilution methods were 67.3% and 76.1%, respectively. Ceftazidime, minocycline, doxycycline, levofloxacin, and rifampin demonstrated acceptable discrepancy and agreement rates.

The overall rates of essential and categorical agreement between the Etest and agar dilution methods were 67.3% and 76.1%, respectively. Ceftazidime, minocycline, doxycycline, levofloxacin, and rifampin demonstrated acceptable discrepancy and agreement rates.

**Figure 1.** Categorical agreement between the disk diffusion and agar dilution methods for the antimicrobial susceptibility testing of E. anophelis. The broken line indicates an agreement rate of 90%.

**Figure 2.** Essential agreement and categorical agreement between the Etest and agar dilution methods for the antimicrobial susceptibility testing of E. anophelis. The broken line indicates an agreement rate of 90%.
4. Discussion

The antimicrobial susceptibility of *E. anophelis* has been reported by studies conducted in several countries, including Singapore [7,8], Hong Kong [9], South Korea [10], Taiwan [11,12], and the United States [13]. These studies have concurrently demonstrated *E. anophelis* to exhibit drug resistance to most β-lactams, β-lactam/lactamase inhibitor combinations, aminoglycosides, and carbapenems, irrespective of the testing techniques used. However, inconsistent AST results were reported for some antibiotics. According to the results of the CLSI-recommended agar dilution assay, we examined the multidrug-resistant characteristics of *E. anophelis*. Among the 14 antimicrobial agents tested in this study, only minocycline, doxycycline, rifampin, and levofloxacin were mostly effective against *E. anophelis*. These 14 antibiotics tested exhibit their bacteriostatic or bactericidal activity via different mechanisms. β-Lactam antibiotics (piperacillin, piperacillin–tazobactam, ceftazidime, and cefepime) target the penicillin-binding proteins and kill bacteria by inhibiting the synthesis of cell walls. Aminoglycosides (gentamicin and amikacin) and tetracyclines/glycylcycline (minocycline, doxycycline, and tigecycline) inhibit protein synthesis by binding to the 30S ribosomal subunit. Fluoroquinolones (ciprofloxacin and levofloxacin) act by inhibiting DNA topoisomerases (DNA gyrase and topoisomerase IV). Sulfamethoxazole inhibits the synthesis of dihydrofolic acid and trimethoprim inhibits thymidine and DNA synthesis. Rifampicin inhibits bacterial DNA-dependent RNA polymerase. Vancomycin binds to the D-Ala-D-Ala of cell walls and inhibits cell wall synthesis [20]. With regard to rifampin, it is known that rifampin is less active against Gram-negative bacilli because it does not readily penetrate the outer membrane of these bacteria [21]. The mechanism for the low rifampin MICs of *E. anophelis* is not clear and warrants further investigation.

The disk diffusion method is an inexpensive, convenient, and excellent AST approach for many microorganisms. Nevertheless, our study revealed that this method exhibited poor performance in the AST of *E. anophelis*. Only ceftazidime, minocycline, levofloxacin, and rifampin were considered acceptable for AST executed through the disk diffusion method. Moreover, the most critical concern of using the disk diffusion method for *E. anophelis* AST is the unacceptable high rate of very major errors.

In the Etest method, the antibiotic gradient diffusion strips constitute a convenient tool for AST. Our study revealed acceptable rates of error and agreement between the Etest and agar dilution methods for ceftazidime, minocycline, doxycycline, levofloxacin, and rifampin. Among these antibiotics, only minocycline, doxycycline, levofloxacin, and rifampin were potentially effective against *E. anophelis*. Moreover, we observed a considerable discrepancy and a poor rate of agreement between the Etest and agar dilution methods. The Etest method underestimated the MICs of all antimicrobial agents tested in this study, except for rifampin. The tendency of the Etest to underestimate MICs has been reported for other microorganisms [22,23]. This false-susceptible predisposition resulted in high rates of very major errors for many antibiotics tested. This is a critical concern for clinicians because patients might be inappropriately treated and die due to these false-susceptible testing results.

When investigating 25 *E. anophelis* isolates from the Wisconsin outbreak, Perrin et al. [13] used the disk diffusion method for AST determination and found susceptibility to piperacillin (100%), piperacillin–tazobactam (92%), cefepime (92%), and ciprofloxacin (92%). In addition, Lau et al. [9] examined 17 *E. anophelis* isolates from Hong Kong by using the disk diffusion method and demonstrated the following susceptibility rates for various agents: ceftazidime, 100%; ciprofloxacin, 100%; trimethoprim–sulfamethoxazole, 70.6%; and vancomycin (100%). These AST results obtained using the disk diffusion method are nearly contradictory to our findings, which indicate that *E. anophelis* isolates were completely resistant to these antibiotics. Moreover, vancomycin cannot penetrate the outer membrane to access the D-Ala-D-Ala binding sites on cell wall, and therefore it is not effective against Gram-negative bacteria, except some *Neisseria* species [24]. Our study revealed a high very major error rate and low categorical agreement rate for these antibiotics through the
disk diffusion method. These differences in susceptibility between the studies could be attributed to the geographic variation as well as false susceptibility.

5. Conclusions

*E. anophelis* has recently become an emerging life-threatening infection in humans. Accurately evaluating antimicrobial susceptibility is imperative for patient care. We suggest that the disk diffusion and Etest methods are not an acceptable alternative for all AST approaches for *E. anophelis*. AST through the disk diffusion and Etest methods could be reliably performed for only some antibiotics.

Author Contributions: Conceptualization, J.-N.L.; data curation, C.-T.C., J.-N.L., C.-H.L., C.-H.Y. and Y.-H.H.; formal analysis, J.-N.L. and Y.-H.H.; funding acquisition, J.-N.L.; methodology, J.-N.L.; resources, C.-H.L.; supervision, J.-N.L.; validation, J.-N.L., C.-H.L., C.-H.Y. and Y.-H.H.; writing—original draft, C.-T.C., J.-N.L. and C.-H.Y.; writing—review and editing, C.-T.C., J.-N.L., C.-H.L., C.-H.Y. and Y.-H.H. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants EDPI108068/EDAHP109046 from E-Da Hospital and MOST 108-2314-B-214-004/109-2314-B-214-006-MY2 from the Ministry of Science and Technology, Taiwan.

Institutional Review Board Statement: This study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of E-Da Hospital (EMRP-107-139).

Informed Consent Statement: The need for patient informed consent was waived by the Institutional Review Board of E-Da Hospital because the retrospective analysis of routine cultures posed no more than minimal risk of harm to the subjects.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Henriques, I.S.; Araújo, S.; Azevedo, J.S.N.; Alves, M.S.; Chouchani, C.; Pereira, A.; Correia, A. Prevalence and diversity of carbapenem-resistant bacteria in untreated drinking water in Portugal. *Microb. Drug Resist.* 2012, 18, 531–537. [CrossRef] [PubMed]

2. Yung, C.F.; Maiwald, M.; Loo, L.H.; Soong, H.Y.; Tan, C.B.; Lim, P.K.; Li, L.; Tan, N.W.; Chong, C.Y.; Tee, N.; et al. *Elizabethkingia anophelis* and association with tap water and handwashing, Singapore. *Emerg. Infect. Dis.* 2018, 24, 1730–1733. [CrossRef] [PubMed]

3. Kyritsi, M.A.; Mouchtouri, V.A.; Pournaras, S.; Hadjichristodoulou, C. First reported isolation of an emerging opportunistic pathogen (*Elizabethkingia anophelis*) from hospital water systems in Greece. *J. Water Health* 2018, 16, 164–170. [CrossRef] [PubMed]

4. King, E.O. Studies on a group of previously unclassified bacteria associated with meningitis in infants. *Am. J. Clin. Pathol.* 1959, 31, 241–247. [CrossRef]

5. Nicholson, A.C.; Gulyik, C.A.; Whitney, A.M.; Humrighouse, B.W.; Graziano, J.; Emery, B.; Bell, M.; Loparov, V.; Juíng, P.; Gartin, J.; et al. Revisiting the taxonomy of the genus *Elizabethkingia* using whole-genome sequencing, optical mapping, and MALDI-TOF, along with proposal of three novel *Elizabethkingia* species: *Elizabethkingia bruuni* sp. nov., *Elizabethkingia ursingii* sp. nov., and *Elizabethkingia occulta* sp. nov. *Antonie Leeuwenhoek* 2018, 111, 55–72. [CrossRef]

6. Kämpfer, P.; Matthews, H.; Glaeser, S.P.; Martin, K.; Lodders, N.; Faye, I. *Elizabethkingia anophelis* sp. nov., isolated from the midgut of the mosquito *Anopheles gambiae*. *Int. J. Syst. Evol. Microbiol.* 2011, 61, 2670–2675. [CrossRef] [PubMed]

7. Teo, J.; Tan, S.Y.; Tay, M.; Ding, Y.; Kjellberg, S.; Givskov, M.; Lin, R.T.; Yang, L. First Case of *E. anophelis* outbreak in an intensive-care unit. *Lancet* 2013, 382, 855–856. [CrossRef] [PubMed]

8. Chew, K.L.; Cheng, B.; Lin, R.T.; Teo, J.W. *Elizabethkingia anophelis* is the dominant *Elizabethkingia* species found in blood cultures in Singapore. *J. Clin. Microbiol.* 2018, 56. [CrossRef] [PubMed]

9. Lau, S.K.; Chow, W.N.; Foo, C.H.; Curreem, S.O.; Lo, G.C.; Teng, J.L.; Chen, J.H.; Ng, R.H.; Wu, A.K.; Cheung, I.Y.; et al. *Elizabethkingia anophelis* bacteremia is associated with clinically significant infections and high mortality. *Sci. Rep.* 2016, 6, 26045. [CrossRef] [PubMed]

10. Han, M.S.; Kim, H.; Lee, Y.; Kim, M.; Ku, N.S.; Choi, J.Y.; Yong, D.; Jeong, S.H.; Lee, K.; Chong, Y. Relative prevalence and antimicrobial susceptibility of clinical isolates of *Elizabethkingia* species based on 16S rRNA gene sequencing. *J. Clin. Microbiol.* 2017, 55, 274–280. [CrossRef] [PubMed]

11. Lin, J.N.; Lai, C.H.; Yang, C.H.; Huang, Y.H.; Lin, H.H. Clinical manifestations, molecular characteristics, antimicrobial susceptibility patterns and contributions of target gene mutation to fluoroquinolone resistance in *Elizabethkingia anophelis*. *J. Antimicrob. Chemother.* 2018, 73, 2497–2502. [CrossRef] [PubMed]
12. Cheng, Y.H.; Perng, C.L.; Jian, M.J.; Cheng, Y.H.; Lee, S.Y.; Sun, J.R.; Shang, H.S. Multicentre study evaluating matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically isolated Elizabethkingia species and analysis of antimicrobial susceptibility. *Clin. Microbiol. Infect.* 2019, 25, 340–345. [CrossRef]

13. Perrin, A.; Larssonneur, E.; Nicholson, A.C.; Edwards, D.J.; Gundlach, K.M.; Whitney, A.M.; Gulvik, C.A.; Bell, M.E.; Rendueles, O.; Curry, J.; et al. Evolutionary dynamics and genomic features of the *Elizabethkingia anophelis* 2015 to 2016 Wisconsin outbreak strain. *Nat. Commun.* 2017, 8, 15483. [CrossRef] [PubMed]

14. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing, M100*, 30th ed.; CLSI: Wayne, PA, USA, 2020.

15. Clinical and Laboratory Standards Institute. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, M07*, 11th ed.; CLSI: Wayne, PA, USA, 2018.

16. Kelesidis, T.; Karageorgopoulos, D.E.; Kelesidis, I.; Falagas, M.E. Tigecycline for the treatment of multidrug-resistant *Enterobacteriaceae*: A systematic review of the evidence from microbiological and clinical studies. *J. Antimicrob. Chemother.* 2008, 62, 895–904. [CrossRef] [PubMed]

17. Food and Drug Administration (USA). FDA-Identified Interpretive Criteria. 2019. Available online: https://www.fda.gov/drugs/development-resources/tigecycline-injection-products (accessed on 7 July 2020).

18. Humphries, R.M.; Ambler, J.; Mitchell, S.L.; Castanheira, M.; Dingle, T.; Hindler, J.A.; Koeth, L.; Sei, K.; CLSI Methods Development and Standardization Working Group of the Subcommittee on Antimicrobial Susceptibility Testing. CLSI methods development and standardization working group best practices for evaluation of antimicrobial susceptibility tests. *J. Clin. Microbiol.* 2018, 56. [CrossRef]

19. Food and Drug Administration (USA). Antimicrobial Susceptibility Test (AST) Systems—Class II Special Controls Guidance for Industry and FDA. 2007. Available online: https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/antimicrobial-susceptibility-test-ast-systems-class-ii-special-controls-guidance-industry-and-fda (accessed on 7 July 2020).

20. Hutchings, M.I.; Truman, A.W.; Wilkinson, B. Antibiotics: Past, present and future. *Curr. Opin. Microbiol.* 2019, 51, 72–80. [CrossRef] [PubMed]

21. Goldstein, B.P. Resistance to rifampicin: A review. *J. Antimicrob. Chemother.* 2014, 67, 625–630. [CrossRef] [PubMed]

22. Simpson, I.N.; Gisby, J.; Hemingway, C.P.; Durodie, J.; Macpherson, I. Evaluation of mupirocin E-test for determination of isolate susceptibility: Comparison with standard agar dilution techniques. *J. Clin. Microbiol.* 1995, 33, 2254–2259. [CrossRef]

23. Luber, P.; Bartelt, E.; Genschow, E.; Wagner, J.; Hahn, H. Comparison of broth microdilution, E test, and agar dilution methods for antibiotic susceptibility testing of *Campylobacter jejuni* and *Campylobacter coli*. *J. Clin. Microbiol.* 2003, 41, 1062–1068. [CrossRef] [PubMed]

24. Butler, M.S.; Hansford, K.A.; Blaskovich, M.A.; Halai, R.; Cooper, M.A. Glycopeptide antibiotics: Back to the future. *J. Antimicrob. Chemother.* 2014, 67, 631–644. [CrossRef] [PubMed]